Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19
Signal Transduct Target Ther
.
2020 Nov 3;5(1):258.
doi: 10.1038/s41392-020-00374-6.
Authors
Tarek Mohamed Abd El-Aziz
1
2
,
Ahmed Al-Sabi
3
,
James D Stockand
4
Affiliations
1
Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229-3900, USA. mohamedt1@uthscsa.edu.
2
Zoology Department, Faculty of Science, Minia University, El-Minia, 61519, Egypt. mohamedt1@uthscsa.edu.
3
College of Engineering and Technology, American University of the Middle East, Kuwait, Kuwait.
4
Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229-3900, USA.
PMID:
33144565
PMCID:
PMC7607365
DOI:
10.1038/s41392-020-00374-6
No abstract available
Publication types
Comment
MeSH terms
Betacoronavirus*
COVID-19
Coronavirus Infections*
Humans
Pandemics*
Peptidyl-Dipeptidase A*
Pneumonia, Viral*
SARS-CoV-2
Substances
Peptidyl-Dipeptidase A
Grants and funding
R01 DK113816/DK/NIDDK NIH HHS/United States
R01 DK117909/DK/NIDDK NIH HHS/United States